MAPT and Alzheimer disease: It is important to note that the authors observed a significant variation in the AD salivary tau levels and relatively low sensitivity and specificity of pTau396/t‐tau levels to distinguish AD and normal controls and, thus, cautioned against the utility of this test as a clinical biomarker.